Drug Search Results
More Filters [+]

BPT-264

Alternative Names: BPT-264, BPT264
Latest Update: 2022-11-01
Latest Update Note: Clinical Trial Update

Product Description

Bright Peak has engineered an enhanced IL-2 cytokine harboring specific modifications to amino acid side chains to uniquely block binding to IL2Rbeta and simultaneously enhance binding to IL2Ralpha, creating an IL-2 mutein that preferentially expands and activates Tregs. Bright Peak’s IL-2 autoimmune cytokine payload can also be conjugated to antibodies as part of their Immunocytokine platform. It is a PEG-IL2 AID (Sourced from: https://brightpeaktx.com/pipeline/)

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bright Peak Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BPT-264

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Autoimmune Disease Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title